{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:44:58Z","timestamp":1784760298067,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"crossref","award":["P4-0127"],"award-info":[{"award-number":["P4-0127"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"crossref","award":["NKP- 21-5"],"award-info":[{"award-number":["NKP- 21-5"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 La Marat\u00f3 de TV3","doi-asserted-by":"crossref","award":["201832-30 and 202135-30"],"award-info":[{"award-number":["201832-30 and 202135-30"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003549","name":"Hungarian Scientific Research Fund","doi-asserted-by":"crossref","award":["K 132870"],"award-info":[{"award-number":["K 132870"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients infected with SARS-CoV-2 risk co-infection with Gram-positive bacteria, which severely affects their prognosis. Antimicrobial drugs with dual antiviral and antibacterial activity would be very useful in this setting. Although glycopeptide antibiotics are well-known as strong antibacterial drugs, some of them are also active against RNA viruses like SARS-CoV-2. It has been shown that the antiviral and antibacterial efficacy can be enhanced by synthetic modifications. We here report the synthesis and biological evaluation of seven derivatives of teicoplanin bearing hydrophobic or superbasic side chain. All but one teicoplanin derivatives were effective in inhibiting SARS-CoV-2 replication in VeroE6 cells. One lipophilic and three perfluoroalkyl conjugates showed activity against SARS-CoV-2 in human Calu-3 cells and against HCoV-229E, an endemic human coronavirus, in HEL cells. Pseudovirus entry and enzyme inhibition assays established that the teicoplanin derivatives efficiently prevent the cathepsin-mediated endosomal entry of SARS-CoV-2, with some compounds inhibiting also the TMPRSS2-mediated surface entry route. The teicoplanin derivatives showed good to excellent activity against Gram-positive bacteria resistant to all approved glycopeptide antibiotics, due to their ability to dually bind to the bacterial membrane and cell-wall. To conclude, we identified three perfluoralkyl and one monoguanidine analog of teicoplanin as dual inhibitors of Gram-positive bacteria and SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41598-022-20182-y","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:07:44Z","timestamp":1664183264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria"],"prefix":"10.1038","volume":"12","author":[{"given":"Ilona","family":"Bereczki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vimberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"L\u0151rincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrietta","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"K\u00e9ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Batta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mitrovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janko","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ron","family":"Zsigmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Hajd\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"L\u0151rincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-9481","authenticated-orcid":false,"given":"D\u00e1vid","family":"Bajusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hodek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-7352","authenticated-orcid":false,"given":"Jan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l","family":"Herczegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"Borb\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"20182_CR1","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"20182_CR2","doi-asserted-by":"publisher","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","volume":"65","author":"WP Painter","year":"2022","unstructured":"Painter, W. P. et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 65, e02428\u2013e02520. https:\/\/doi.org\/10.1128\/AAC.02428-20 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20182_CR3","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2021","unstructured":"Vangeel, L. et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antivir. Res. 198, 105252. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105252 (2021).","journal-title":"Antivir. Res."},{"key":"20182_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2009.01.003","volume":"82","author":"L Naesens","year":"2009","unstructured":"Naesens, L. et al. Anti-influenza virus activity and structure\u2013activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. Antivir. Res. 82, 89\u201394 (2009).","journal-title":"Antivir. Res."},{"key":"20182_CR5","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1021\/jm900950d","volume":"52","author":"G Pint\u00e9r","year":"2009","unstructured":"Pint\u00e9r, G. et al. Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycone derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. J. Med. Chem. 52, 6053\u20136061 (2009).","journal-title":"J. Med. Chem."},{"key":"20182_CR6","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1016\/j.bmcl.2012.09.079","volume":"22","author":"A Sipos","year":"2012","unstructured":"Sipos, A. et al. Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycone with remarkable antibacterial and antiviral activities. Bioorg. Med. Chem. Lett. 22, 7092\u20137096 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"20182_CR7","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1016\/j.bmcl.2014.06.018","volume":"24","author":"I Bereczki","year":"2014","unstructured":"Bereczki, I. et al. Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: Synthesis and antiviral studies. Bioorg. Med. Chem. Lett. 24, 3251\u20133254 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"20182_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ejmech.2018.08.058","volume":"157","author":"Z Sz\u0171cs","year":"2018","unstructured":"Sz\u0171cs, Z. et al. Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycone derivatives as new anti-influenza virus agents. Eur. J. Med. Chem. 157, 1017\u20131030 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"20182_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/ph14111111","volume":"14","author":"I Bereczki","year":"2021","unstructured":"Bereczki, I. et al. Natural apocarotenoids and their synthetic glycopeptide conjugates inhibit SARS-CoV-2 replication. Pharmaceuticals 14, 1111. https:\/\/doi.org\/10.3390\/ph14111111 (2021).","journal-title":"Pharmaceuticals"},{"key":"20182_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.05.935387","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv https:\/\/doi.org\/10.1101\/2020.02.05.935387 (2020).","journal-title":"bioRxiv"},{"key":"20182_CR11","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1002\/jmv.26925","volume":"93","author":"G Ceccarelli","year":"2021","unstructured":"Ceccarelli, G. et al. The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). J. Med. Virol. 93, 4319\u20134325 (2021).","journal-title":"J. Med. Virol."},{"key":"20182_CR12","doi-asserted-by":"publisher","first-page":"104792","DOI":"10.1016\/j.antiviral.2020.104792","volume":"178","author":"T Tang","year":"2020","unstructured":"Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R. & Daniel, S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antivir. Res. 178, 104792. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104792 (2020).","journal-title":"Antivir. Res."},{"key":"20182_CR13","doi-asserted-by":"publisher","first-page":"e1009500","DOI":"10.1371\/journal.ppat.1009500","volume":"17","author":"M Laporte","year":"2021","unstructured":"Laporte, M. et al. The SARS-CoV-2 and other human coronavirus Spike proteins are fine-tuned towards temperature and proteases of the human airways. PLoS Pathog. 17, e1009500. https:\/\/doi.org\/10.1371\/journal.ppat.1009500 (2021).","journal-title":"PLoS Pathog."},{"key":"20182_CR14","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","volume":"291","author":"N Zhou","year":"2016","unstructured":"Zhou, N. et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem. 291, 9218\u20139232 (2016).","journal-title":"J. Biol. Chem."},{"key":"20182_CR15","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.ijbiomac.2020.08.166","volume":"164","author":"PK Tripathi","year":"2020","unstructured":"Tripathi, P. K. et al. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2. Int. J. Biol. Macromol. 164, 2622\u20132631 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"20182_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41429-019-0164-1","volume":"72","author":"Z Sz\u0171cs","year":"2019","unstructured":"Sz\u0171cs, Z. et al. New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE. J. Antibiot. 72, 524\u2013534 (2019).","journal-title":"J. Antibiot."},{"key":"20182_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/ph13070139","volume":"13","author":"Z Sz\u0171cs","year":"2020","unstructured":"Sz\u0171cs, Z. et al. Reprogramming of the antibacterial drug vancomycin results in potent antiviral agents devoid of antibacterial activity. Pharmaceuticals 13, 139. https:\/\/doi.org\/10.3390\/ph13070139 (2020).","journal-title":"Pharmaceuticals"},{"key":"20182_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acsinfecdis.1c00367","volume":"8","author":"Y Acharya","year":"2022","unstructured":"Acharya, Y., Bhattacharyya, S., Dhanda, G. & Haldar, J. Emerging roles of glycopeptide antibiotics: Moving beyond gram positive bacteria. ACS Infect. Dis. 8, 1\u201328 (2022).","journal-title":"ACS Infect. Dis."},{"key":"20182_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/acsinfecdis.7b00258","volume":"4","author":"MAT Blaskovich","year":"2018","unstructured":"Blaskovich, M. A. T. et al. Developments in glycopeptide antibiotics. ACS Infect. Dis. 4, 715\u2013735 (2018).","journal-title":"ACS Infect. Dis."},{"key":"20182_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/cmdc.202000260","volume":"15","author":"I Bereczki","year":"2020","unstructured":"Bereczki, I. et al. Synthesis of antiviral perfluoroalkyl derivatives of teicoplanin and vancomycin. ChemMedChem 15, 1661\u20131671 (2020).","journal-title":"ChemMedChem"},{"key":"20182_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41429-020-0313-6","volume":"73","author":"Z Sz\u0171cs","year":"2020","unstructured":"Sz\u0171cs, Z. et al. N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium. J. Antibiot. 73, 603\u2013614 (2020).","journal-title":"J. Antibiot."},{"key":"20182_CR22","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/adsc.201600501","volume":"358","author":"R Beniazza","year":"2016","unstructured":"Beniazza, R. et al. Benzophenone vs. copper\/benzophenone in light-promoted atom transfer radical additions (ATRAs): Highly effective iodoperfluoroalkylation of alkenes\/alkynes and mechanistic studies. Adv. Synth. Catal. 358, 2949\u20132961 (2016).","journal-title":"Adv. Synth. Catal."},{"key":"20182_CR23","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0960-894X(03)00051-9","volume":"13","author":"J Wanner","year":"2003","unstructured":"Wanner, J. et al. A new and improved method for deglycosidation of glycopeptide antibiotics exemplified with vancomycin, ristocetin, and ramoplanin. Bioorg. Med. Chem. Lett. 13, 1169\u20131173 (2003).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"20182_CR24","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3390\/pharmaceutics13122028","volume":"13","author":"ST Le","year":"2021","unstructured":"Le, S. T. et al. The very first modification of pleuromutilin and lefamulin by photoinitiated radical addition reactions\u2014Synthesis and antibacterial studies. Pharmaceutics 13, 2028. https:\/\/doi.org\/10.3390\/pharmaceutics13122028 (2021).","journal-title":"Pharmaceutics"},{"key":"20182_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.pathol.2020.09.012","volume":"52","author":"S Stelzer-Braid","year":"2020","unstructured":"Stelzer-Braid, S. et al. Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. Pathology 52, 760\u2013763 (2020).","journal-title":"Pathology"},{"key":"20182_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41422-020-00450-0","volume":"31","author":"G Wang","year":"2020","unstructured":"Wang, G. et al. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res. 31, 17\u201324 (2020).","journal-title":"Cell Res."},{"key":"20182_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1039\/C6MD00585C","volume":"8","author":"P Sarkar","year":"2017","unstructured":"Sarkar, P., Yarlagadda, V., Ghosh, C. & Haldar, J. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. MedChemComm 8, 516\u2013533 (2017).","journal-title":"MedChemComm"},{"key":"20182_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41429-018-0120-5","volume":"72","author":"V Vimberg","year":"2019","unstructured":"Vimberg, V. et al. Fluorescence assay to predict activity of the glycopeptide antibiotics. J. Antibiot. 72, 114\u2013117 (2019).","journal-title":"J. Antibiot."},{"key":"20182_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/cr030103a","volume":"105","author":"D Kahne","year":"2005","unstructured":"Kahne, D., Leimkuhler, C., Lu, W. & Walsh, C. Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. 105, 425\u2013448 (2005).","journal-title":"Chem. Rev."},{"key":"20182_CR30","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1002\/chem.201303310","volume":"20","author":"J Trevi\u00f1o","year":"2014","unstructured":"Trevi\u00f1o, J. et al. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Chem. Eur. J. 20, 7363\u20137372 (2014).","journal-title":"Chem. Eur. J."},{"key":"20182_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/AAC.39.3.781","volume":"39","author":"DA Beauregard","year":"1995","unstructured":"Beauregard, D. A., Williams, D. H., Gwynn, M. N. & Knowles, D. J. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39, 781\u2013785 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"20182_CR32","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1021\/acs.jmedchem.0c02124","volume":"64","author":"A Stevaert","year":"2021","unstructured":"Stevaert, A. et al. Betulonic acid derivatives interfering with human coronavirus 229E replication via the nsp15 endoribonuclease. J. Med. Chem. 64, 5632\u20135644 (2021).","journal-title":"J. Med. Chem."},{"key":"20182_CR33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1515\/bchm3.1995.376.6.385","volume":"376","author":"M Dolinar","year":"1995","unstructured":"Dolinar, M., Maganja, D. B. & Turk, V. Expression of full-length human procathepsin L cDNA in Escherichia coli and refolding of the expression product. Biol. Chem. Hoppe Seyler 376, 385\u2013388 (1995).","journal-title":"Biol. Chem. Hoppe Seyler"},{"key":"20182_CR34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nprot.2006.77","volume":"1","author":"BY Feng","year":"2006","unstructured":"Feng, B. Y. & Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550\u2013553 (2006).","journal-title":"Nat. Protoc."},{"key":"20182_CR35","doi-asserted-by":"publisher","first-page":"19403","DOI":"10.1074\/jbc.M115.651463","volume":"290","author":"S Tomar","year":"2015","unstructured":"Tomar, S. et al. Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): Implications for nsp5 regulation and the development of antivirals. J. Biol. Chem. 290, 19403\u201319422 (2015).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20182-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20182-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20182-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T10:27:37Z","timestamp":1664188057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20182-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20182"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20182-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16001"}}